The Longitudinal Pediatric Data Resource (LPDR) is a secure informatics system designed to enable enhanced data collection, sharing, management and analysis for conditions identified as part of newborn screening or for conditions that may benefit from newborn screening. The NBSTRN team worked with subject matter experts, the Joint Committee*, our Clinical Centers Workgroup, grantees and the National Library of Medicine (NLM) in a national consensus-based process to identify standards-based, disease-specific datasets that would be useful in both clinical care and research efforts. These datasets were then integrated into a set of data capture, data management, and data almanac tools that leverage the Research Electronic Data Capture (REDCap) system. The web-based system allows clinicians to access electronic case report forms (CRFs) and download updated paper CRFs for the disorders with role-based access. Data is collected as part of a standard clinic visit and entered into a centralized or institutionally-enabled REDCap instance for aggregation, management and analysis, with a future goal of electronic data entry at the time of the clinic visit. Disease specific electronic CRFs incorporate a uniform consensus dataset as well as disease-specific datasets. To date, 45 individual metabolic conditions, one neuromuscular disorder, and four lysosomal storage disorders have been entered into the LPDR. A series of data elements encompassing demographics, socioeconomic factors, natural history, genetics, disease symptoms, disease progression, and treatment protocols are included and linked to definitions and national standards through an accompanying data almanac. This resource will be made available to the newborn screening research community, where it is expected to accelerate the development of new technologies and treatments, methodological, outcomes, and public health research of newborn screening. Currently 1300 cases of inborn errors of metabolism are included in the inaugural LPDR. The development of a consensus data set for the long-term follow-up of newborns facilitates the translation of new discoveries into clinical practice to improve health outcomes and further scientific understanding. The use of this approach in pilot studies serves a model for future initiatives as genomic technologies begin to be applied to disease screening and management across the lifespan.
Available Data Summary
Common Data Element Sets
- General (For All Conditions)
- Assessments and Examinations
Disease/Injury Related Events
Participant/Subject Characteristics
Participant/Subject History and Family Hisotry
Disease/Injury Related Events
Outcomes and End Points
Treatments/Intervention Data - Amino Acid
- Argininemia (ARG)
Argininosuccinic aciduria (ASA)
Benign Hyperphenylalaninemia (H-PHE)
Biopterin defect in cofactor biosynthesis (BIOPT BS)
Biopterin defect in cofactor regeneration (BIOPT REG)
Citrullinemia type I (CIT)
Citrullinemia type II (CIT II)
Classic Phenylketonuria (PKU)
Homocystinuria (HCY)
Hypermethioninemia (MET)
Maple syrup urine disease (MSUD)
Tyrosinemia type III (TYR III)
Tyrosinemia type II (TYR II)
Tyrosinemia type I (TYR I) - Fatty Acid
- Short-chain acyl-CoA dehydrogenase deficiency (SCAD)
Trifunctional protein deficiency (TFP)
Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)
2, 4-Dienoyl-CoA reductase deficiency (DE RED)
Carnitine acylcarnitine translocase deficiency (CACT)
Carnitine palmitoyltransferase type I deficiency (CPT IA) Carnitine palmitoyltransferase type II deficiency (CPT II)
Carnitine uptake defect/carnitine transport defect (CUD)
Glutaric acidemia type II (GA2)
Long-chain L-3 hydroxyacyl-CoA dehydrogenase deficiency (LCHAD)
Medium-chain acyl-CoA dehydrogenase deficiency (MCAD)
Medium-chain ketoacyl-CoA thiolase deficiency (MCAT)
Medium/short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency (M/SCHAD) - Lysosomal Storage Disease
- Niemann Pick Types A and B
Fabry - Organic Acid
- Isobutyrylglycinuria (IBG)
Isovaleric acidemia (IVA)
2-Methyl-3-hydroxybutyric aciduria (2M3HBA)
2-Methylbutyrylglycinuria (2MBG)
3-Methylcrotonyl-CoA carboxylase deficiency (3-MCC)
3-Methylglutaconic aciduria (3MGA)
Beta-Ketothiolase deficiency (bKT)
Glutaric acidemia type I (GA1)
Holocarboxylase synthetase deficiency (MCD)
Propionic acidemia (PROP)
Malonic acidemia (MAL)
Methylmalonic acidemia (cobalamin disorders) (CblA,B)
Methylmalonic acidemia (methylmalonyl-CoA mutase) (MUT)
Methylmalonic acidemia with homocystinuria (Cbl C,D) - Spinal Muscular Atrophy
- Spinal muscular atrophy (SMA)
- Other
- Galactoepimerase deficiency (GALE)
Galactokinase deficiency (GALK)
Biotinidase deficiency (BIOT)
Classic galactosemia (GALT)
LPDR Projects
-
Severe Combined Immunodeficiencies
Michele Caggana, ScD
New York State, Department of Health-WadsworthCenter
August 2010 - June 2011 -
Lysosomal Storage Disorders Collaborative
Melissa Wasserstein, MD
Mount Sinai School of Medicine
September 4, 2012 - May 31, 2017 -
Inborn Errors of Metabolism
Cynthia Cameron, PhD and Susan Berry, MD
Michigan Public Health Institute and University of Minnesota
April 15, 2011 - February 29, 2016 -
Spinal Muscular Atrophy
Kathryn J. Swoboda, MD, FACMG
Motor Disorders Research Program Department of Neurology - University of Utah
April 20, 2011 - March 31, 2016